

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



LDE225 (phosphate)

Item No. 16263

CAS Registry No.: 1218778-77-8

Formal Name: rel-N-[6-[(2R,6S)-2,6-dimethyl-4-

> morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-

carboxamide, diphosphate


Synonyms: Erismodegib, NVP-LDE225, Sonidegib

 $C_{26}H_{26}F_3N_3O_3 \bullet 2H_3PO_4$ MF:

681.5 FW: **Purity:** ≥98% UV/Vis.: λ_{max} : 276 nm A crystalline solid Supplied as:

-20°C Storage: ≥2 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

LDE225 (phosphate) is supplied as a crystalline solid. A stock solution may be made by dissolving the LDE225 (phosphate) in the solvent of choice, which should be purged with an inert gas. LDE225 (phosphate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LDE225 (phosphate) in these solvents is approximately 10 mg/ml.

LDE225 (phosphate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LDE225 (phosphate) should first be dissolved in ethanol and then diluted with the agueous buffer of choice. LDE225 (phosphate) has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LDE225 is a smoothened (Smo) antagonist ($IC_{50}s = 1.3$ and 2.5 nM for mouse and human Smo, respectively). In vivo, LDE225 (20 mg/kg per day) inhibits Gli1 mRNA expression and prevents tumor growth in an orthotopic Ptch^{+/-} p53^{-/-} medulloblastoma mouse allograft model. Formulations containing LDE225 have been used in the treatment of locally advanced basal cell carcinomas.

Reference

1. Pan, S., Wu, X., Jiang, J., et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med. Chem. Lett. 1(3), 130-134 (2010).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/14/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM